Marginal zone lymphoma with severe rashes: A case report

Figure 1 Skin appearance before and after treatment. A-D: Skin manifestations before treatment; E-H: Patient skin after six treatment cycles.

Figure 2 Computed tomography scans before and after treatment. A-D: Computed tomography (CT) results at the time of diagnosis. Orange arrows represent axillary lymph node enlargement, hilar lymph node enlargement, splenomegaly and inguinal lymph node enlargement, respectively (orange arrow); E-H: CT results after three courses of treatment, which indicated that the lymph nodes were significantly reduced, although spleen retraction was not obvious (orange arrow); I-L: CT results after six courses of treatment, showing that the lymph nodes almost disappeared and the spleen significantly shrank (orange arrow).

Figure 3 Immunohistochemical staining of pathological biopsy at diagnosis. A: Hematoxylin-eosin (HE) staining of lymph nodes at 10 × magnification; B: CD3 (partial +); C: CD20 (+); D: CD5 (partial +); E: CD23 (-); F: Bcl-2 (+); G: Ki67 (about 15%); H: CyclinD1 (-); I: P53 (about 60%); J: HE staining of the skin at 10 × magnification. Immunohistochemical staining of lymph nodes at 10 × magnification (B-I).

Figure 4 Bone marrow biopsy at diagnosis. A: Hematoxylin-eosin (HE) staining of bone marrow at 10 × magnification; B: HE staining of bone marrow at 40 × magnification.

Figure 5 Bone marrow immunophenotyping at diagnosis. Abnormal B lymphocytes were observed in bone marrow samples, accounting for 6.67% of nuclear cells. A: Abnormal B lymphocytes expressed CD19 and CD20; B: Abnormal B lymphocytes did not express CD5 and CD10; C: Abnormal B lymphocytes did not express CD23 and CD38; D: Abnormal B lymphocytes did not express CD11c and CD103; E: Abnormal B lymphocytes did not express CD11c and CD25; F: Abnormal B lymphocytes expressed Kappa, not Lambda.